On the other hand, Gargiulo et al.’s retrospective multicenter study [31] analyzed the long-term persistence (“drug survival”) of interleukin (IL) inhibitors, specifically IL-12/23, IL-17, and IL-23, in 5932 treatment courses for moderate-to-severe plaque psoriasis. This evidence concerns the gene IL17A and psoriasis vulgaris.